Aims and scope

*Please note that Expert Opinion on Orphan Drugs converted to a full Open Access journal from Volume 11 (2023). Previous
volumes will continue to provide access through a Pay to Read model.

Expert Opinion on Orphan Drugs [e-ISSN 2167-8707] is an international journal publishing rigorously peer-reviewed review articles and original papers on rare diseases and orphan drugs. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Orphan Drugs aims to draw a spotlight on diseases that do not have a high prevalence but have a huge impact on patients and their clinicians, through valuable and high-quality expert insights. In a field which is ever-growing and changing, Expert Opinion on Orphan Drugs is committed to acting as a reliable beacon of guidance and support for researchers, clinicians, patients and advocacy groups in order to optimise research, development, management and quality of life of rare disease patients.

Articles focus on the following key areas:

• Diagnostics, pharmacogenomics and screening;
• Public health and epidemiology;
• Drug development;
• Lead generation and discovery;
• Early or late phase clinical trials;
• Regulatory issues;
• Post-marketing safety and treatment outcomes.
  
  

The journal also welcomes solicited and unsolicited papers including Drug Evaluations, specifically reviewing the pharmacological properties, clinical potential/clinical efficacy, safety and, if applicable, HE/OR data on a particular orphan drug, as well as Original Research papers and Editorials.

Read the Instructions for Authors for information on how to submit your article. For any pre-submission enquiries, please contact the Commissioning Editor.

Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.